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The hemodynamic effects of intracoronary leukotriene 
C4 (0.3 to 10.0 p.g) in seven anesthetized dogs with nor•
mal and severely narrowed coronary arteries were ex•
amined. Intracoronary leukotriene C4 caused a signifi•
cant dose-related reduction in coronary blood flow in 
both normal and narrowed coronary arteries with no 
effect on heart rate or mean arterial pressure. However, 
left ventricular end-diastolic pressure increased at the 
10.0 p.g dose. The reduction of blood flow in normal and 
narrowed coronary arteries in response to leukotriene 
C4 was similar. At the peak effects of leukotriene C4 , 
there was evidence of intracoronary thromboxane A2 
release. To examine the contribution of thromboxane A2 
release to the coronary vasoconstrictor effects of leu•
kotriene C4, dogs were administered leukotriene C4 after 
indomethacin pretreatment. The decrease in coronary 
Leukotrienes, a group of compounds released from activated 
white blood cells, have potent vasoactive properties, De•
rived through lipoxygenation of arachidonic acid from cell 
membrane phospholipids. these compounds are biologically 
active components of SRS-A (slow-reacting substance of 
anaphylaxis) released during anaphylactic reactions (1.2), 
Leukotrienes have also been shown (3) to be mediators of 
coronary vasoconstriction. decrease myocardial contractile 
force and induce arrhythmias, 
In Langendorff guinea pig heart preparations. intraaortic 
administration of leukotriene C4• 0 4 and E4 causes dose•
related reductions in coronary blood flow as well as ven•
tricular arrhythmias and electrocardiographic evidence of 
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blood flow was not significantly affected by pretreatment 
of the animals with indomethacin. However, indometh•
acin lowered baseline levels ofthromboxane 8 2 and blocked 
the release of thromboxane A2 after leukotriene C4 
administration. 
Thus, intracoronary leukotriene C4 causes direct dose•
dependent decrease in coronary blood flow of similar 
magnitude in both normal and narrowed coronary ar•
teries. These coronary hemodynamic effects of leuko•
triene C4 in dogs are not mediated by release of throm•
boxane Az• Leukotriene C4 released from activated 
leukocyte in the intracoronary thrombus or in the in•
jured myocardium may reduce coronary blood flow and 
adversely influence the fate of the affected myocardial 
tissue. 
(J Am Coil CardioI1985;6:1047-51) 
myocardial ischemia (4), Woodman and Dusting (5) ad•
ministered leukotriene C4 • 0 4 and E4 into the normal coro•
nary arteries of anesthetized dogs and observed dose•
dependent decreases in coronary blood flow without sys•
temic hemodynamic effects, The vasoconstrictor effects of 
leukotrienes on narrowed coronary arteries, if similar to 
those on normal coronary arteries, could be potentially det•
rimental. The purpose of this investigation, therefore, was 
to examine the comparative hemodynamic effects of leu•
triene C4 in normal and narrowed coronary arteries of the 
anesthetized dog, In addition, we examined the influence 
of cyclooxygenase inhibition on the coronary hemodynamic 
effects of leukotriene C+. 
Methods 
Preparation of animals. Coronary hemodynamic ef•
fects of leukotriene C4 were evaluated in seven mongrel 
dogs unselected for age or sex with a mean body weight of 
25 kg (range 23 to 30). The dogs were anesthetized with 
sodium pentobarbital (30 mg/kg body weight). intubated 
and ventilated with a Harvard respirator to maintain arterial 
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blood gases within the physiologic range (pH 7.35 to 7.45). 
A left thoracotomy was performed in the fifth intercostal 
space and the heart was suspended in a pericardial cradle. 
Approximately 2 cm of the left anterior descending and left 
circumflex coronary arteries was dissected free from adja•
cent tissues. A polyethylene catheter was inserted into a 
diagonal branch of the left anterior descending artery and 
advanced to the left main coronary artery, its position con•
firmed at the end of the experiment by opening the vessel. 
Equisensitive Millar Mikro-tip pressure catheters were po•
sitioned in the thoracic aorta and left ventricle through a 
carotid artery. Electromagnetic flow probes (Biotronix) were 
placed around the left anterior descending and circumflex 
coronary arteries. A small catheter was placed in the coro•
nary sinus for collection of blood samples during leukotriene 
C4 infusion. A plastic occluder was placed around the left 
anterior descending coronary artery to create a "critical" 
stenosis that limited the reactive hyperemic response to a 
I 0 second total left anterior descending artery occlusion but 
did not change the blood flow at rest. The hemodynamic 
variables, left anterior descending and circumflex coronary 
blood flows, heart rate and aortic and left ventricular end•
diastolic pressures, were continuously recorded by a mul•
tichannel recorder (Electronics for Medicine). 
Leukotriene C4 administration. After the hemody•
namic variables were stable on multiple measurements for 
at least 15 minutes, the dogs were administered 0.5 ml of 
saline solution (solvent for leukotriene C4 ) into the left main 
coronary artery for 10 seconds. They were then administered 
Ieukotriene C4 (0.3, 1.0, 3.0 and 10.0 JLg) in a random 
fashion in a total volume of 0.5 ml over 10 seconds into 
the left main coronary artery. At the peak coronary effect 
of 3.0 JLg, blood samples were obtained from the coronary 
sinus for measurement of thromboxane B2 . 
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After recording the hemodynamic effects of leukotriene 
C4 and the collection of blood samples, the dogs were given 
indomethacin (5 mg/kg) intravenously. After 30 to 45 min•
utes, when hemodynamic variables were stable, the animals 
were again administered saline solution and leukotriene C4 
(0.3 to 10.0 JLg) into the left main coronary artery. Hemo•
dynamic effects were recorded at each dose. Blood was 
collected from the coronary sinus after the 3.0 JLg dose of 
Ieukotriene C4 was administered. 
Materials. Leukotriene C4 was obtained from J. Ro•
kach, PhD of Merck-Frosst, Dorval, Canada, kept at -70°C 
before use and dissolved in physiologic saline solution. In•
domethacin (Merck) was dissolved in ethanol-sodium bi•
carbonate solution. 
Collection of blood samples. Blood samples were col•
lected only if blood was free-flowing in sterile heparinized 
disposable plastic syringes, transferred into polypropylene 
test tubes and immediately placed on ice. The test tubes 
contained 0.5 ml of indomethacin (30 JLM) and ethylene•
diaminetetraacetic acid (EDTA) (4.5 mM) to which 2.0 ml 
of blood was added. The blood samples were immediately 
centrifuged at 2,500 g for 10 minutes, and plasma samples 
were stored at - 70°C for measurement of thromboxane B2 
by radioimmunoassay. 
Measurement of thromboxane 8 2 , Immunoreactive 
thromboxane B2 was measured as the stable hydrolysis prod•
uct of thromboxane A2. The technique for measurement has 
been described previously (6). Lyophilized standards, 3H_ 
thromboxane B2 and lyophilized antibodies raised in rabbits 
were obtained from New England Nuclear. Cross-reactivity 
for the thromboxane B2 antibody has been described pre•
viously (7). Duplicate or triplicate measurements in different 
volumes of blood were averaged and reported as picograms 
per milliliter. 
Figure 1. Representative hemodynamic effects of 
leukotriene C4 (L TC4 ) on normal circumflex (Cx) 
and narrowed left anterior descending (LAD) coro•
nary arteries. An increase in left ventricular end•
diastolic pressure (L VEDP) occurred at the 10.0 
jLg dose. CBF = coronary blood flow; MAP 
mean arterial pressure. 
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Figure 2. Effects of leukotriene C4 on blood flow in normal and 
narrowed coronary arteries. Intracoronary leukotriene C4 caused 
similar dose-related decreases in blood flow in normal and nar•
rowed coronary arteries. 
Statistical evaluation. Data are expressed as mean ± 
SE. Student's t test (paired and unpaired data) and analysis 
of variance were used for significance. 
Results 
Hemodynamic effects of leukotriene C4 • In the control 
state, intracoronary administration of normal saline solution 
(solvent) caused minimal changes in coronary blood flow 
in the patent circumflex and narrowed left anterior descend•
ing coronary arteries (+ 9 ± 3% and + 2 ± 2%, respec•
tively). Intracoronary administration of leukotriene C4 re•
sulted in significant dose-dependent decreases in coronary 
blood flow (- 5 to - 24%) in both the patent circumflex 
and the narrowed left anterior descending coronary arteries 
(Fig. I). The decreases in blood flow were similar in both 
arteries (Fig. 2). The peak effect was seen in approximately 
30 seconds with a return to baseline in 2 minutes. There 
were no changes in heart rate or arterial pressure; however, 
the 10 JLg dose in some instances caused a transient increase 
in left ventricular end-diastolic pressure and a decrease in 
arterial pressure (Table I). 
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Figure 3. Effects of Ieukotriene C4 on blood flow in a normal left 
circumflex coronary artery before and after indomethacin admin•
istration. The magnitude of decrease in coronary blood flow caused 
by leukotriene C4 after indomethacin was similar to that of the 
preindomethacin state. Data expressed as mean ± SE. 
Hemodynamic effects of leukotriene C4 after indo•
methacin. After 30 to 45 minutes, there was a slight in•
crease in arterial pressure and a slight decrease in coronary 
blood flow, at rest, but these changes were not significant. 
Intracoronary administration of leukotriene C4 caused dose•
dependent decreases in both left anterior descending (Fig. 
3) and circumflex coronary (Fig. 4). blood flows. The mag•
nitude of reduction in coronary flow was similar to that in 
the preindomethacin state. Changes in arterial pressure and 
left ventricular end-diastolic pressure after administration 
of leukotriene C4 were also similar to those of the prein•
domethacin state (Table 1). 
Plasma levels of thromboxane 8 2, Coronary venous 
plasma thromboxane 8 2 assay showed a marked increase in 
thromboxane B2 levels in response to leukotriene C4 (599 
± 45 to 1,937 ± 417 pg/ml, p :::; 0.02). Indomethacin 
administration lowered the rest levels of thromboxane 8 2 
(230 ± 20 pg/ml, p :::; 0.05). Indomethacin also abolished 
the leukotriene C4-induced increase in the plasma levels of 
thromboxane 8 2 (241 ± 16 pg/ml). 
Table 1. Hemodynamic Effects of Leukotriene C4 in Seven Dogs 
Percent Change From Baseline 
Before Indomethacin After Indomethacin 
LTC4 (p.g) AP LVEDP HR AP LVEDP HR 
0.3 I± 0 0 0 0 0 
1.0 -3 ± 3 0 0 2 ± 2 I ± 2 0 
3.0 -I ± I 3 ± 3 0 0 6 ± 6 0 
10.0 -I ± I 9 ± 6* 0 -5 ± 3 16 ± 5* 0 
Data expressed as mean ± SE. *p :5 0.05 compared with baseline. AP = arterial pressure; HR = heart 
rate; L TC4 = leukotriene C4 ; L VEDP = left ventricular end-diastolic pressure. 
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Figure 4. Effects of leukotriene C4 on blood flow in a narrowed 
left anterior descending coronary artery before and after indo•
methacin administration. The magnitude of decrease in coronary 
blood flow caused by leukotriene C4 after indomethacin was similar 
to that of the preindomethacin state. Data expressed as mean ± 
SE. 
Discussion 
Leukotriene C4 and coronary flow. Leukotriene C4 has 
been previously reported to reduce coronary blood flow and 
myocardial contractile force in isolated guinea pig heart 
preparations (4) and to produce coronary vasoconstriction 
in normal coronary arteries of dogs (5,8) and pigs (9). Our 
study confirms that administration of leukotriene C4 into the 
left main coronary artery causes dose-dependent decreases 
in coronary blood flow and shows that the magnitude of 
decrease in blood flow is similar in normal and narrowed 
coronary arteries. Our study also indicates that this decrease 
in blood flow is not mediated by products of the cyclo•
oxygenase pathway because coronary hemodynamic changes 
were of similar magnitude with or without pretreatment of 
the animals with indomethacin. 
We did not observe any significant effects of moderate 
doses of leukotriene C4 (0.3 to 3.0 j.tg) on heart rate, arterial 
pressure or left ventricular end-diastolic pressure, although 
a large dose (10 j.tg) caused a transient increase in left 
ventricular end-diastolic pressure. Because coronary per•
fusion pressure and left ventricular end-diastolic pressure 
were unchanged, it is likely that the effects of leukotriene 
C4 on blood flow are a result of direct action on the coronary 
arteries. Other investigators (5,8) also noted lack of signif•
icant effect of intracoronary leukotrienes on systemic hemo•
dynamic variables in dogs. Ezra et al. (9), however, reported 
an increase in left ventricular end-diastolic pressure and a 
greater decrease in coronary flow in pigs given I to 3 j.tg 
of leukotriene C4. Letts et al. (10) suggested that leuko•
trienes may have a direct toxic effect on the myocardium 
in isolated guinea pig hearts. A more pronounced decrease 
in coronary flow and increase in left ventricular end-diastolic 
pressure after leukotriene C4 administration in pigs com-
lACC Vol. 6. No.5 
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pared with dogs may relate to species differences in sen•
sitivity to leukotriene C4 • 
Role of leukocytes in myocardial ischemia. There has 
been a growing interest in the role of leukocytes and their 
interaction with platelets in myocardial ischemia (11-14). 
Although the precise role of leukotrienes in the evolution 
and course of myocardial ischemia is unknown, it has been 
shown (15) that polymorphonuclear leukocytes invade in•
jured myocardium and release reactive and cytotoxic ma•
terials that facilitate phagocytosis and scar formation. Stim•
ulated neutrophils have been demonstrated (16) to trigger 
cell membranes to release arachidonic acid that is metab•
olized by cyclooxygenase and Iipoxygenase pathways to 
prostaglandins, thromboxanes and leukotrienes. A recent 
study (14) revealed that infarcted myocardium produced 10 
times more 12-hydroperoxyeicosatetraenoic acid, an inter•
mediate product in the biosynthesis of leukotrienes, from 
14C-labeled arachidonic acid than does the normal myocar•
dium. It can be postulated that release of leukotrienes from 
activated leukocytes during myocardial injury could com•
promise coronary blood flow in the narrowed coronary ar•
teries. Our study clearly indicates this potential for detri•
mental effects of leukotriene C4 . 
Thromboxane A2 and myocardial ischemia. Increased 
levels of thromboxane A2 metabolite have been found in 
the coronary venous blood of patients during pacing-induced 
angina and in patients with coronary vasospasm as well as 
in experimental animals during ischemia (17-19). Data from 
our study also suggest the release of thromboxane A2 in the 
coronary venous blood during reduction in coronary flow 
induced by leukotriene C4 . Because thromboxane A2, a ma•
jor cyclooxygenase product in platelets, promotes platelet 
aggregation and causes coronary vasoconstriction, treatment 
of patients or animals with antiplatelet drugs to reduce isch•
emia has seemed warranted. However, several investigators 
(20,21) who examined the effects of antiplatelet drugs have 
shown no consistent benefit from such treatment. It has, 
therefore, been proposed that thromboxane A2 is unlikely 
to be a primary factor in the reduction of coronary blood 
flow, although it may mediate local changes in blood flow 
during ischemia. Our present results indicate that throm•
boxane A2 inhibition has no influence on the potentially 
detrimental effects of leukotriene C4 on coronary blood flow. 
Implications of study. Recent animal studies (11-14) 
have shown that infarct size is dependent, in part, on leu•
kocyte accumulation in the myocardium. Depletion of leu•
kocytes (12,14) or use of agents such as BW755C, a 
lipoxygenase and cyclooxygenase inhibitor (14,22), and na•
fazatrom Bay g6557, a lipoxygenase inhibitor (23), de•
creases leukocyte accumulation in the infarcted myocardium 
and reduces infarct size. It is possible that leukotriene pro•
duction by activated neutrophils in injured myocardium ac•
counts for some degree of coronary vasoconstriction seen 
in myocardial ischemia. It is also possible that reports (24) 
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of myocardial ischemic events during allergic and anaphy•
lactic reactions relate to the release of leukotrienes and sub•
sequent reductions in coronary blood flow, Leukotriene C•
induced coronary flow reduction may have potentially det•
rimental effects in myocardium perfused by narrowed ath•
erosclerotic coronary arteries, Development of agents that 
block the lipoxygenation of arachidonic acid or prevent the 
accumulation of leukocytes in the myocardium may be ben•
eficial in modulating coronary blood flow reduction and 
reducing infarct size, 
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